CDXS News and Press, Codexis Inc. From 05/05/20

REDWOOD CITY, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc., a leading protein engineering company and developer of novel biotherapeutics, announces the appointment of Stefan Lutz, Ph.D. as Senior Vice President, Research and Karl A. Schoene, Ph.D. as Senior Vice President, Develop...

REDWOOD CITY, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report first quarter 2020 financial results after market close on Thursday, May 7, 2020.  Codexis management will hold an investment comm...

Investors were having their doubts about Codexis (NASDAQ: CDXS) well before the coronavirus pandemic punished stock markets. At first, those concerns focused on whether the stock could live up to its premium valuation. Later, investors grew frustrated with a slower-than-expected pace of prog...

Codexis (NASDAQ: CDXS ) has signed a strategic collaboration and license agreement with Takeda Pharmaceutical ( OTCPK:TKPHF ) for the research and development of novel gene therapies for certain disease indications, including the treatment of lysosomal storage disorders and blood factor de...

REDWOOD CITY, Calif., March 23, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc., a leading protein engineering company and developer of novel biotherapeutics, announces the signing of a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (Takeda) for the research...

Appili Therapeutics (APLI CN) initiated with Buy rating and C$4 (602% upside) price target at Maxim Group. More news on: Aphria Inc., Codexis, Inc., HEXO Corp., Healthcare stocks news, Stocks on the move, , Read more ...

Well, that wasn't what investors were expecting .  Codexis (NASDAQ: CDXS) announced disappointing full-year 2019 operating results on Feb. 27. It ended September needing a relatively small amount of fourth-quarter sales to meet full-year 2019 revenue guidance, but managed to miss the ...

Shares of Codexis (NASDAQ: CDXS) fell as much as 20% today after the company reported fourth-quarter and full-year 2019 operating results. The enzyme engineering company missed its own projections for full-year 2019 revenue, whiffed on Wall Street's full-year 2019 revenue expectations, and i...

Image source: The Motley Fool. Codexis   (NASDAQ: CDXS) Q4 2019 Earnings Call Feb 27, 2020 , 4:30 p.m. ET Operator Continue reading

Codexis, Inc. (CDXS) Q4 2019 Earnings Conference Call February 27, 2020 4:30 PM ET Company Participants Jody Cain - LHA Investor Relations John Nicols - President and Chief Executive Officer Ross Taylor - Chief Financial Officer Conference Call Participants Matt Hewitt - Cr...